ArticleJCO precision oncology2026
Foundation Model Based on Routine Magnetic Resonance Imaging for Brain Tumor Molecular Profiling and Progression Prediction.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine Learning for Radiomics in Oncology: Challenges, Limitations, and Future Directions.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo build a self-supervised magnetic resonance imaging (MRI) foundation model from routine clinical scans and to test whether it can support key glioma-related applications, including post-therapy imaging outcome characterization and molecular marker inference. MATERIALS AND
methodsWe created the Unified Multimodal Brain Imaging Foundation (UMBIF) model and pretrained it in a self-supervised manner using 51,029 routine brain MRI examinations collected across multiple institutions. Pretraining used a hybrid objective that couples masked-image reconstruction with contrastive representation learning to encourage anatomically and clinically informative embeddings. The pretrained UMBIF encoder was then adapted to downstream multicenter data sets to predict (1) post-treatment radiographic outcomes and (2) molecular biomarkers, including
resultsRelative to self-supervised initialization derived from natural-image corpora or from approaches emphasizing only large tumor-area crops (self-supervised learning [SSL]-ImageNet and SSL-Cerebral), the UMBIF encoder-decoder design captured richer, more task-relevant features and consistently improved downstream discrimination. The best pretrained model achieved an accuracy of 0.899 (AUC, 0.815) for post-treatment radiographic outcome characterization. For molecular profiling, it reached accuracies/AUCs of 0.898/0.916 for 1p/19q codeletion, 0.829/0.896 for
conclusionUMBIF showed robust transferability to both post-therapy imaging assessment and molecular status prediction in glioma. By leveraging large-scale self-supervised pretraining to boost performance while reducing dependence on manual annotations, the framework may facilitate more efficient and reliable diagnostic workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.